
HomeThe Life Sciences Fund Amsterdam is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Amsterdam Metropolitan Area. The fund targets companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, medical devices and other high technology opportunities that offer venture capital returns. The close co-operation between the fund, the technology transfer offices of the Life Sciences Center Amsterdam and the Amsterdam Biomed Cluster, enables the fund to facilitate the transfer of technology to the private sector and to provide emerging technology companies and university researchers with vital seed funding and specialized financial and technical assistance. |
Latest news04-11-2011
Sigmascreening receives approval from Dutch Health Council
More...20-05-2011
ACS BIOMARKER B.V. closes financing round and appoints new CEO
More...06-12-2010
Simgascreening describes its vision in AMC Magazine (Dutch)
More...30-11-2010
Regenesance ontvangt financiering om nieuwe medicijnen te ontwikkelen voor patiënten met sterke neurondegeneratie
More...30-11-2010
Regenesance closes financing round
More... |